Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR has 3.14B shares outstanding.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.35, indicating elevated leverage, while an interest coverage ratio of 6.43 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR posted a negative return on equity (ROE) of -2.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.10, reflecting losses generated across the asset base. The company generates approximately 10.51M in revenue per employee across its workforce of 47,242.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Takeda Pharmaceutical Co. Ltd. Sponsored ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR recorded 3.53B in income tax expense. The company reported a pretax loss of -14.00B and -17.56B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 14, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR's stock has gained approximately 31.38% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR generated 496.41B in revenue and converted that into -17.56B in net income, yielding earnings per share of -5.52. EBITDA reached 72.38B, while operating income came in at 51.73B.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR holds 56.70B in cash and equivalents against 530.91B in total debt, resulting in a net debt position of 481.37B. Total book value stands at 812.27B, with working capital of 41.45B providing operational flexibility.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR produced 88.79B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -36.50B in capital expenditures, free cash flow totaled 52.29B - equivalent to 16.58 per share.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR posted a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of -3.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. Sponsored ADR paid dividends of 5.68 per share. The dividend payout ratio of -102.30 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.